Hematopoietic and Lymphoid Cell NeoplasmNCT05496972
Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology
An observational study of Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Survey Administration
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Apr 2021to 1 Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: MD Anderson Cancer Center
Who may be able to join
- Patients will be eligible if they are aged 18 or older and have undergone at least 1 telemedicine encounter (video visit) with the radiation oncology department at MD Anderson or its affiliates within 2 months from the initiation of the study (and prospectively as the study enrolls). This would include weekly see visits, follow-up visits, or consultations
- English speaking
- Access to email and internet to complete the survey
- Attending physicians in the radiation oncology department who have utilized telemedicine will be contacted to fill out surveys reflecting their experience
Who cannot join
- Protected populations such as adults unable to consent, pregnant women, prisoners, and individuals who are not yet adults will be excluded
Trial locations and contacts
1 site in 1 country.
About this study
To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.
Read the detailed description
Primary Objective:
To characterize patient and provider satisfaction with telemedicine in RO
Secondary Objective:
- To provide evidence for or against the use of telemedicine in radiation oncology (RO)
- To assess the feasibility of and value added by telemedicine in RO
- To describe barriers and facilitators to telemedicine in RO
- To identify preferred use cases for telemedicine in RO
- Being tested
- Survey Administration
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Survey AdministrationBehavioural
Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
| Study group | Role | What they receive |
|---|---|---|
| Telemedicine Visits | Participants are asked to fill out a survey about their experience. Receives: Behavioral: Survey Administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient satisfaction survey with telemedicine in radiation oncology (RO)
Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers.
Measured: through study completion and average of one year.
Provider satisfaction survey with telemedicine in radiation oncology (RO)
Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers.
Measured: through study completion and average of one year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2022
- Study start21 Apr 2021
- Primary completion1 Jul 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic and Lymphoid Cell NeoplasmStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chenyang Wang, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05496972
- Sponsor's protocol ID
- 2020-1063
- Other IDs
- NCI-2021-09908
- Status last verified
- May 2026
- First submitted
- 8 Aug 2022
- Last updated
- 22 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology
- ClinicalTrials.gov ID
- NCT05496972
- Acronym / sponsor ID
- 2020-1063
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 21 Apr 2021 (actual)
- Primary completion
- 1 Jul 2027 (estimated)
- Study completion
- 1 Jul 2027 (estimated)
- First posted
- 11 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.
Detailed description
Primary Objective:
To characterize patient and provider satisfaction with telemedicine in RO
Secondary Objective:
- To provide evidence for or against the use of telemedicine in radiation oncology (RO)
- To assess the feasibility of and value added by telemedicine in RO
- To describe barriers and facilitators to telemedicine in RO
- To identify preferred use cases for telemedicine in RO
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Telemedicine Visits | – | Behavioral: Survey AdministrationParticipants are asked to fill out a survey about their experience. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- MD Anderson Cancer Center
Key inclusion criteria (4 listed)
- Patients will be eligible if they are aged 18 or older and have undergone at least 1 telemedicine encounter (video visit) with the radiation oncology department at MD Anderson or its affiliates within 2 months from the initiation of the study (and prospectively as the study enrolls). This would include weekly see visits, follow-up visits, or consultations
- English speaking
- Access to email and internet to complete the survey
- Attending physicians in the radiation oncology department who have utilized telemedicine will be contacted to fill out surveys reflecting their experience
Key exclusion criteria (1 listed)
- Protected populations such as adults unable to consent, pregnant women, prisoners, and individuals who are not yet adults will be excluded
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Survey AdministrationPatients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine | Behavioural | Telemedicine Visits |
Primary outcome
Patient satisfaction survey with telemedicine in radiation oncology (RO)
Time frame: through study completion and average of one year.
Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers.
Provider satisfaction survey with telemedicine in radiation oncology (RO)
Time frame: through study completion and average of one year.
Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Hematopoietic and Lymphoid Cell Neoplasm
Not yet recruitingPhase 4
MACE and BTK Inhibitors
Hematologic Cancer, MACE
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chenyang Wang, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient satisfaction survey with telemedicine in radiation oncology (RO) (time frame: through study completion and average of one year.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.